Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07796308 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Terazosin And Metabolic Engagement in Alzheimer's Disease

Name: Terazosin And Metabolic Engagement in Alzheimer's Disease — clinical trial record (NCT07796308)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: TAME-AD

StatusNot Yet Recruiting

PhasePhase 2

SponsorQiang Zhang

Started2027-08-01

View on ClinicalTrials.gov ↗

The TAME-AD trial will be a randomized, double-blind, placebo-controlled Phase IIa clinical trial to evaluate the metabolic target engagement of terazosin for the treatment of Alzheimer's disease.

Trial Details

NCT Number	NCT07796308
Lead Sponsor	Qiang Zhang
Conditions	Alzheimer s Disease
Enrollment	100 participants
Start Date	2027-08-01
Primary Completion	2031-07-31 (estimated)
Study Completion	2032-07-31 (estimated)
Updated on ClinicalTrials.gov	2026-09-01